About This Tool

The Succimer (DMSA) Dose Calculator is a clinical support tool designed to assist healthcare professionals in determining appropriate dosing regimens for lead poisoning. Succimer is a chelating agent that binds to heavy metals in the bloodstream, facilitating their excretion from the body. This calculator applies standard, FDA-approved protocols to provide patient-specific dosing based on weight or Body Surface Area (BSA), ensuring adherence to established therapeutic guidelines.

Outputs

After entering the patient's data, the calculator provides a comprehensive dosing plan, which includes:

  • Recommended Dose: The practical dose in milligrams (mg), rounded to the nearest 50 mg for administration using 100 mg capsules.
  • Capsule Count: The corresponding number of 100 mg capsules required for the recommended dose.
  • Initial Therapy Schedule: A 5-day regimen detailing the dose to be administered every 8 hours, along with the total daily dose.
  • Maintenance Therapy Schedule: A 14-day continuation regimen with the dose administered every 12 hours, including the total daily dose.
  • Calculation Basis: A summary of the input parameters used for the calculation, such as patient weight, height (if used), BSA, and the selected dosing method.

How to Use

To use the calculator effectively, follow these steps:

  1. Enter Patient Weight: Input the patient's weight and select the appropriate unit (kg or lbs).
  2. Enter Patient Height: If using the BSA-based method, input the patient's height and select the unit (cm or in). This field can be left blank for weight-based calculations.
  3. Select Calculation Basis: Choose between the standard weight-based calculation (10 mg/kg/dose) or the BSA-based method (350 mg/m²/dose). The weight-based option is selected by default.
  4. Calculate: Click the "Calculate Dose" button to generate the complete 19-day treatment plan.

Dosing Overview

The standard treatment course for succimer in lead poisoning lasts 19 days and is divided into two phases to maximize efficacy while monitoring for adverse effects.

  • Initial Phase (Days 1-5): Therapy begins with a higher frequency of administration, typically 10 mg/kg or 350 mg/m² per dose, given every 8 hours. This induction phase rapidly reduces blood lead levels.
  • Maintenance Phase (Days 6-19): After the initial 5 days, the dosing frequency is reduced to every 12 hours for the remaining 14 days. The per-dose amount remains the same. This maintenance phase continues to promote lead excretion.

Adequate hydration is crucial throughout the entire course of therapy to support renal excretion of the lead-chelator complex.

Switching

Decisions regarding switching to, from, or between chelation therapies should be made by a clinician experienced in managing lead poisoning. If a patient does not respond adequately to a course of succimer or if blood lead levels rebound significantly after treatment, a subsequent course may be considered. A minimum of two weeks is recommended between courses to allow for metal redistribution and to monitor for any adverse effects.

Missed Dose

If a dose of succimer is missed, the patient or caregiver should be instructed to administer it as soon as they remember. However, if it is almost time for the next scheduled dose, they should skip the missed dose and resume the regular dosing schedule. It is important not to administer a double dose to make up for a missed one.

Safety Alerts

Succimer is generally well-tolerated, but monitoring is essential. Key safety considerations include:

  • Hematologic Effects: Mild to moderate neutropenia has been observed. A baseline complete blood count (CBC) with differential should be obtained before therapy and monitored weekly during treatment.
  • Hepatic Effects: Transient elevations in liver enzymes (ALT/AST) can occur. Liver function tests should be monitored before and during therapy.
  • Gastrointestinal Effects: Nausea, vomiting, and diarrhea are the most common side effects. A metallic taste in the mouth may also be reported.
  • Hydration: Maintaining adequate fluid intake is important to facilitate urinary excretion of lead and prevent dehydration.

FAQ

Why does the calculator round the dose?

The calculated dose is rounded to the nearest 50 mg to allow for practical administration using the available 100 mg capsules. This avoids the need for complex dose splitting and aligns with common clinical practice.

What is the difference between weight-based and BSA-based dosing?

Weight-based dosing (mg/kg) is the most common method. Body Surface Area (BSA)-based dosing (mg/m²) considers both height and weight and may be preferred by some clinicians, particularly in patients with atypical body compositions, as it can provide a more precise metabolic-based dose.

Can succimer capsules be opened for administration?

Yes. For patients, particularly young children, who cannot swallow capsules whole, the capsules can be opened and the contents sprinkled on a small amount of soft food, such as applesauce or jam.

What if I only know the patient's weight but not their height?

You can still calculate the dose using the "Weight-based" option. Patient height is only required when selecting the "BSA-based" calculation method.

How long is a full course of succimer therapy?

A standard treatment course as recommended by the FDA label is 19 days, consisting of 5 days of initial therapy followed by 14 days of maintenance therapy.

Is this calculator suitable for both children and adults?

Yes, the dosing principles (mg/kg or mg/m²) apply to both pediatric and adult patients. The calculator is a tool to apply these principles, but clinical judgment remains paramount.

What blood lead level warrants treatment with succimer?

The decision to initiate chelation therapy is based on the blood lead level (BLL) and the patient's clinical presentation. According to CDC guidelines, chelation therapy is typically considered for children with a BLL of 45 µg/dL or greater.

Does the calculator account for patients with kidney problems?

No. The calculator does not adjust for renal or hepatic impairment. Succimer and its metabolites are excreted via the kidneys, and dose adjustments may be necessary in patients with renal insufficiency. Consult a specialist for such cases.

References

PRO
Ad-Free Access
$3.99 / month
  • ✓ No Interruptions
  • ✓ Faster Page Loads
  • ✓ Support Content Creators
Subscribe Now